In This Section

New Paradigms for Targeting Adenosine Receptors: Basic and Translational Applications

Tuesday April 09, 2019

2:00 pm - 3:30 pm Eastern Time (ET)

Room W206 A

BEH CVP MP TCP

Chair :

Ross Corriden
Merck

Lauren May
Monash Institute of Pharmaceutical Sciences, Monash University



Adenosine is one of the body’s most vital cytoprotective molecules, mediating its effects through the adenosine family of G protein-coupled receptors. This receptor family has an essential role in physiology and pathophysiology, particularly in response to stress and injury, and therefore represents potential targets for the treatment of major global health burdens such as ischaemia-reperfusion injury, neuropathic pain and inflammation. This symposium will highlight recent advances in the mechanistic understanding and therapeutic exploitation of adenosine receptors across a variety of disease states, providing novel approaches for overcoming the preclinical-clinical bottleneck in targeting this vital receptor family.

Speakers

Kenneth Jacobson - National Institute of Diabetes and Digestive and Kidney Disease, NIH

Translational Successes and Failures of Adenosine Receptor Therapeutics

Laura Heitman - LACDR, Leiden University

Drug-Target Binding Kinetics – A Case for Adenosine Receptors

Lauren May - Monash Institute of Pharmaceutical Sciences, Monash University

Adenosine Receptor Context-Specific Biased Agonism to Treat Ischemic Heart Disease

Joel Linden - La Jolla Institute for Allergy and Immunology

Targeting Adenosine Receptors to Regulate Immune Responses